Background: Whether all types of inhaled corticosteroids (ICSs) would increase the
pneumonia risk in patients with chronic obstructive pulmonary disease (COPD) remains …

Chronic obstructive pulmonary disease (COPD) is a chronic airway inflammation
characterized by fixed airflow limitation and chronic respiratory symptoms, such as cough …

Background Inhaled corticosteroids (ICSs) have been used widely in the maintenance
therapy of COPD. However, whether inhaled therapy containing ICSs can reduce the all …

Both chronic obstructive pulmonary disease and bronchiectasis are highly prevalent
diseases. In both cases, inhaled corticosteroids (ICs) are associated with a decrease in …

Inhaled corticosteroids (ICS) have a class effect of increasing pneumonia risk in patients
with COPD. However, pneumonia incidence varies widely across clinical trials of ICS use in …

The claimed functional basis for ICSs in asthma and COPD is airway selectivity, attained by
inhaling a potent, lipophilic compound with long local dissolution/absorption time. The …

Studies have shown increased nontuberculous mycobacterial pulmonary disease (NTM)
incidence with inhaled corticosteroid (ICS) use in patients with chronic respiratory diseases; …

Despite great advancements in the treatment of chronic airway diseases, improvements in
morbidity and mortality have stalled in recent years. Asthma and chronic obstructive …

Background Inhaled corticosteroids (ICS) afford therapeutic benefits in some COPD patients,
but their widespread use is cautioned due to an increased risk of developing pneumonia …

Inhaled corticosteroids (ICSs) are widely used in chronic obstructive pulmonary disease
(COPD) and in combination with long-acting β2 agonists (LABAs) to reduce exacerbations …